Loading clinical trials...

Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST) | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)

ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg

NCT00442845•Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

View on ClinicalTrials.gov

Summary

Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.
•Triglycerides up to 600 mg/dL.
•History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events

Exclusion Criteria

•Pregnancy or lactation, use of high statin doses (\>40mg) at baseline, liver or renal problems, use of other drugs that would interfere with evaluation of efficacy or cause safety problems, uncontrolled hypertension, diabetes or hypothyroidism, recent cardiac event of procedure, high baseline CPK levels

Locations (121)

Pfizer Investigational Site

Mississauga, Ontario, Cameroon

Pfizer Investigational Site

Calgary, Alberta, Canada

Pfizer Investigational Site

Edmonton, Alberta, Canada

Pfizer Investigational Site

Medicine Hat, Alberta, Canada

Pfizer Investigational Site

Red Deer, Alberta, Canada

Pfizer Investigational Site

Campbell River, British Columbia, Canada

Pfizer Investigational Site

Maple Ridge, British Columbia, Canada

Pfizer Investigational Site

Nanaimo, British Columbia, Canada

Pfizer Investigational Site

New Westminster, British Columbia, Canada

Pfizer Investigational Site

Richmond, British Columbia, Canada

Key Dates

Start Date

January 1, 2003

Primary Completion Date

February 1, 2004

Completion Date

February 1, 2004

Last Updated

February 18, 2021

Enrollment

2,080

Estimated participants

Conditions

Coronary ArteriosclerosisDiabetes Mellitus, Type 2Cerebrovascular AccidentDyslipidemiaPeripheral Vascular Disease

Interventions

Atorvastatin (Lipitor)

DRUG

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC

NCT06241677

CVA (Cerebrovascular Accident)

View study

RECRUITINGNA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use